TP53 and colorectal cancer: In multivariable analysis incorporating known clinicopathological prognostic factors, we showed that low overall mutation burden and mutations in KRAS, BRAF, and TP53 were independently associated with decreased relapse-free survival after colorectal cancer treated with curative intent.